Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

Size: px
Start display at page:

Download "Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans"

Transcription

1 Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans - Acquisitions, Financing, Expansion Initiatives & Strategic Plans MIRAMAR, FL, January 22, Generex Biotechnology Corporation ( (OTCQB:GNBT) ( is happy to provide the investment community with a review of the many accomplishments achieved in 2018, with a vision for growth in 2019 by Generex CEO Joseph Moscato. At the end of 2017, Generex formed a new, wholly-owned subsidiary NuGenerex Distribution Solutions, LLC (NDS), completing the initial organizational restructuring of the company. In January 2018, NDS acquired Empire State Pharmacy LLC in New York and Grainland Pharmacy LLC in Kansas, commencing the Company s strategic plans to establish itself as a presence in the U.S. direct-to-consumer pharmaceuticals business. Since those initial pharmacy acquisitions, Generex has been conducting an extensive audit of a nationwide pharmacy network with database and IT systems that enable a robust direct-to-patient pharmacy program. The results of the audits and acquisition due diligence are forthcoming, allowing Generex to proceed with the planned acquisition in the coming weeks. With the formation of NDS, Generex focused on the acquisition of the assets of the Veneto Group, a Management Services Organization (MSO) that operates a proprietary partnership and service model focused on the physician/patient relationship. With comprehensive solutions that integrate billing, insurance, and reporting from ancillary healthcare providers (pharmacy, labs, DME, imaging), NDS provides efficiencies and convenience and physicians and their patients. Generex is integrating the company s products and services with NDS MSO network of physicians to provide end-to-end solutions from manufacturing to patient point of care to reduce costs, optimize outcomes, and improve patient satisfaction with care. The acquisition and integration of the MSO network and ancillary service providers was announced on November 3, 2018, and was completed in early 2019 with a payment of $15 million in Generex stock at the upmarket price of $2.50 per share, plus a $20 million follow on payment within 90 Days to satisfy current debt obligations. NDS is headquartered in Dallas, TX with over 100 employees operating in 5 states, and plans to expand the business to a total of 27 states over the coming months started well for Generex oncology, as the company s wholly-owned subsidiary Antigen Express was paid an initial $700,000 licensing fee from Shenzhen BioScien Page 1 of 6

2 Pharmaceuticals for the rights to AE37 immunotherapeutic vaccine for the treatment of prostate cancer in China. The company is working with Shenzhen Bioscien on the planning for a Phase II trial of AE37 in prostate cancer to be conducted at sites in the EU. Taking advantage of the 2018 boom in immunotherapy for cancer, Antigen Express was renamed NuGenerex Immuno-Oncology. Generex finalized a research partnership with Merck to conduct a Phase II clinical trial of AE37 in combination with Merck s Keytruda for the treatment of triple-negative breast cancer. The protocol was submitted under an investigational new drug application (IND), which has been allowed by FDA, and is being managed by the NSABP, with enrollment starting in the first quarter of The company worked throughout 2018 to identify opportunities in the immuno-oncology field for acquisitions and partnerships. To that end, Generex Executive Vice President of Research & Development presented an update on the AE37 development program with a talk, Novel Therapeutics in Cancer Immunotherapy at the Immuno-Oncology Summit in Boston, MA together with leading researchers and executives in the field. The company is currently in discussions with potential licensing and development partners to advance the Ii-Key immunotherapeutic vaccine technology, with the objective to spin out NuGenerex Immuno-Oncology as an independent, public, subsidiary company. Generex recently announced a stock dividend for Generex shareholders who will receive 1 share of NuGenerex Immuno-Oncology for every 4 shares held in Generex Biotechnology. The payment date for the dividend is set for February 25, In the diagnostics arena, Generex acquired the remaining 49% of shares in its subsidiary Hema Diagnostic Systems (HDS) for $1, and renamed its now wholly-owned subsidiary NuGenerex Diagnostics (NGDx). The HDS investors released Generex from an outstanding note in the amount of $624, in exchange for shares of the Company s common stock valued at $18.99 per share. As part of the transaction, the HDS investors released the company from notes totaling $13,431, made to HDS prior to the Generex acquisition. Overall, this transaction resulted in $624, plus the Company s 51% share of the HDS debt being removed from Generex corporate debt and added to the Company s stockholders equity, thereby increasing shareholder value. The company filed a Patent for its New Diagnostic Point-of-Care Platform, the Express II, which has applied for a CE Marking from the European Economic Area (EEA) for the commercialization of the NGDx Express II rapid test for syphilis and awaits approval. The company plans to apply for FDA clearance of the Express II Syphilis test in the U.S. market. Page 2 of 6

3 Further, at the end of the year, Generex was able to exchange the warrants associated with the HDS acquisition in exchange for Generex common stock. At the end of 2018, Generex established NuGenerex Therapeutics advancing a strategy to build a regenerative medicine company with the acquisitions of Olaregen Therapeutix and Regentys. Olaregen is preparing to launch the company s first product, Excellagen Wound Conforming Gel, which is FDA cleared for 17 wound healing indications. The company will distribute Excellagen through the proprietary market channels of NDS. Regentys is developing a novel, patented Extra-Cellular Matrix Hydrogel (ECMH) for the treatment of ulcerative colitis and inflammatory bowel diseases. Seeking to add to the portfolio of pharmacy retail products, and focused on the trends in the CBD market, Generex signed an agreement with Puration, Inc. (USOTC: PURA) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water. The CBD used in the NuGenerex CBD HydroHealth product line will be exclusively derived from industrial hemp, now legalized under the 2018 Farm Bill, using a patented extraction process that yields ultra-purified and characterized CBD formulations. By establishing the relationship with Puration, Generex is positioned to lead in the field of cannabinoid medicines. Also, at the end of 2018 and into the beginning of 2019, Generex has built a surgical products manufacturing and supply business through the acquisitions of Pantheon Medical, MediSource Partners, and the publicly traded company Fuse Medical (OTC: FZMD). Together, these companies generate current revenues of over $32 million, with surgical products, biologics, and services that can be utilized by surgeons and podiatrists, including the NDS network of MSO physicians, to increase sales through the company s proprietary market channels. Such end-to-end solutions provide Generex with efficiencies and synergies that will increase revenues and profits. Throughout the first half of 2018, Generex reorganized the company s management team, adding experienced executives to oversee the development, implementation and execution of the company s strategic growth plan. First, Generex announced the appointment of Terry Thompson as Chief Operating Officer, Terry brings a wealth of operational experience in the pharmaceutical industry having been a founding member of the executive team at Medco. Other key appointments continued throughout the year with the additions of Anthony S. Crisci, ESQ., CPA as General Manager & Chief Legal Compliance Officer, Roger Ivey as Executive Vice President and General Counsel, Dick Suedkamp as Executive Vice President of Finance and Accounting, Steve Worster as Chief Compliance Officer, Brad Guy as Chief Human Resource Officer, Anthony J. Dolisi as Chief Page 3 of 6

4 Commercial Officer, and Michelle Starr as Chief Marketing Officer. Biographies of the entire Generex management team can be found on the company web site ( Throughout the past year, Generex has worked to keep investors informed of the company s strategic plans and initiatives. To that end, Joseph Moscato, CEO has presided over 3 conference calls, transcripts of which can be found on the company web site at The major news for Generex in 2018 was the issuance of a 20:1 share dividend in November, in which Generex shareholders received 20 new shares of Generex Biotechnology for every share held on the payment date. This 20:1 dividend rewarded loyal Generex shareholders, not only with their additional personal shares, but also in the financial status of the company. Four major Generex shareholders, including the CEO Joseph Moscato, Director Lawrence Salvo, the previous owner of HDS, and an investment fund contributed their dividend shares to the benefit of the company, creating a Pool of shares that can be used to achieve the company s strategic objectives. Generex has recently used the Pool Shares to pay for acquisition of the Veneto Group assets at the upmarket price of $2.50 per share. These shares were also used in a share exchange with the Olaregen private investors to acquire an additional 9% of the company (on top of the already 51% already owned by Generex) at the up-market price of $2.50 per share. Generex in in negotiations with the Olaregen shareholders to acquire the remaining 40% of the company and achieve 100% ownership of the company. Summing up the years and providing insight into 2019 plans, CEO Joseph Moscato stated, After years of work, our plans for Generex and the NuGenerex family of subsidiary companies is coming into focus for the investment community. We have built an MSO network with ancillary healthcare services, concentrating on the physician patient relationship. We have added complementary companies with FDA cleared devices and approved products that illustrate our philosophy to offer end-to-end solutions to improve not just health, but also the economics of healthcare. We have rewarded our investors with a share dividend, and have announced plans to spin-out our oncology franchise, NuGenerex Immuno-Oncology and the Ii-Key technology with an additional share dividend for Generex shareholders in the new oncology company. We have identified and are in discussions with potential partners to expand the company s product and IP portfolios through licensing, acquisitions, and development agreements. We continue to utilize the Pool Shares for non-dilutive financing to advance our agenda as we build a new Page 4 of 6

5 kind of life science holding company to meet the challenges of tomorrow s healthcare marketplace. He continued, This is just the beginning, as we have just now established the platforms and infrastructure for growth in We have finally completed the audits of the directto-patient pharmacy network, and plan to complete that acquisition in the coming weeks. The pharmacy databases and IT infrastructure will be valuable additions that have significant synergies with Generex and the NuGenerex family of companies. We will complete the recently announced acquisitions in the surgical supply space, and will be announcing additional acquisition opportunities in the field of regenerative medicine, including exosomes and the next generation stem cells. We are expanding the NDS MSO network to 20+ additional states, with plans to expand beyond the current physician specialties of surgery and podiatry to include oncology, geriatrics, and other subspecialties that require ancillary healthcare services for their patient care. Plus, we are in discussions to acquire and integrate a hospital management company that owns a 13- hospital network that provides new market channels and will enable Generex to offer expanded, patient focused services and products was a year to launch the New Generex with a new structure and a focus on acquiring revenue generating companies, and integrating them into the NuGenerex family. This year, we are executing on the operational plans of our service companies, launching our first drug with Excellagen and becoming a force in the regenerative medicine field, and we are realizing the value of our oncology assets through a spin-out strategy for NuGenerex Immuno-Oncology. Through 2019, we will continue to grow and add value to Generex, and we want to thank our investors for believing in our corporate mission to provide physicians, hospitals, and all healthcare providers with an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers. About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. Page 5 of 6

6 In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center. Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. Generex Contact: Generex Biotechnology Corporation Joseph Moscato Todd Falls Extension 222 investor@generex.com Page 6 of 6

Generex Announces Appointment of Executive Management Team

Generex Announces Appointment of Executive Management Team Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation

More information

Acquisition of MST Medical Surgery Technologies Ltd:

Acquisition of MST Medical Surgery Technologies Ltd: Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation

More information

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT

More information

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc.

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc. PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS Announces Name Change to Walker Innovation Inc. Announces Name Change of its United States Patent Utility Service to Haystack IQ Trial Usage of New

More information

ALANCO TECHNOLOGIES INC

ALANCO TECHNOLOGIES INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

Transforming Surgical Robotics. 34 th Annual J.P. Morgan Healthcare Conference January 14, 2016

Transforming Surgical Robotics. 34 th Annual J.P. Morgan Healthcare Conference January 14, 2016 1 Transforming Surgical Robotics 34 th Annual J.P. Morgan Healthcare Conference January 14, 2016 Forward Looking Statements 2 This presentation includes statements relating to TransEnterix s current regulatory

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA

More information

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance Reynolds American Enters Smokeless Tobacco Category Via Acquisition of Conwood $3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category Deal at a Glance 2005 Financial Summary

More information

Acquisition of GEODynamics. December 13, 2017

Acquisition of GEODynamics. December 13, 2017 Acquisition of GEODynamics December 13, 2017 Forward-looking Statements We include the following cautionary statement to take advantage of the "safe harbor" provisions of the Private Securities Litigation

More information

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported

More information

FSIC FRANCHISE. Frequently asked questions

FSIC FRANCHISE. Frequently asked questions Frequently asked questions FSIC FRANCHISE 1. What are the details of the announced transaction? FS Investments ( FS ) and KKR Credit ( KKR ) announced an agreement to form a partnership to provide investment

More information

Scienti c Games Debuts First Skill- Based Slot Machine with Classic Arcade Video Game Favorite -- SPACE INVADERS

Scienti c Games Debuts First Skill- Based Slot Machine with Classic Arcade Video Game Favorite -- SPACE INVADERS Scienti c Games Debuts First Skill- Based Slot Machine with Classic Arcade Video Game Favorite -- SPACE INVADERS Innovative new slot integrates authentic alien shooter bonus game, free games, and an option

More information

KOHLBERG CAPITAL CORPORATION. May 2007

KOHLBERG CAPITAL CORPORATION. May 2007 KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These

More information

Confirms 2013 Financial Guidance

Confirms 2013 Financial Guidance Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared

More information

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your

More information

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third

More information

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be

More information

Investor Presentation & Financial Highlights. November 2018

Investor Presentation & Financial Highlights. November 2018 Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.

More information

UBS Global Healthcare Services Conference February 14, 2006

UBS Global Healthcare Services Conference February 14, 2006 UBS Global Healthcare Services Conference February 14, 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not

More information

Contact: Greg A. Smith Katja Gehrt Marshall & Ilsley Corporation Warburg Pincus

Contact: Greg A. Smith Katja Gehrt Marshall & Ilsley Corporation Warburg Pincus News Release Marshall & Ilsley Corporation 770 North Water Street Milwaukee, WI 53202 414 765-7700 Main 414 298-2921 Fax mibank.com For Release: Immediately Contact: Greg A. Smith Katja Gehrt Marshall

More information

WASHINGTON,D.C FORM8-K. CURRENTREPORT PursuanttoSection13or15(d)ofthe. Date of Report (Date of the earliest event reported): October29,2018

WASHINGTON,D.C FORM8-K. CURRENTREPORT PursuanttoSection13or15(d)ofthe. Date of Report (Date of the earliest event reported): October29,2018 UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 Date of Report (Date of the earliest event reported):

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

Investor Presentation. June 2006

Investor Presentation. June 2006 Investor Presentation June 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, the impact of

More information

the SPD company Dr Clive Simon, Principal, The SPD Company.

the SPD company Dr Clive Simon, Principal, The SPD Company. the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated

More information

Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research

Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research UCLA Research: A Winning Environment $811M+ in research awards for FY2006 3,300

More information

Financing Growth Ventures to Minimize Equity Dilution

Financing Growth Ventures to Minimize Equity Dilution Financing Growth Ventures to Minimize Equity Dilution An entrepreneurial team s mission is to develop and grow its venture and to optimize the management team s equity ownership stake. Significant growth

More information

Halliburton and Baker Hughes Creating the leading oilfield services company

Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Conformis, Inc. (Exact Name of Company as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Conformis, Inc. (Exact Name of Company as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES

EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES I. Introduction EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES Authored By Philip N. Krause Two categories of entrepreneurial ventures: Revenue Model Growth Model this is what we are discussing

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported)

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2019

More information

Page 1 of 5 LEGAL_1:

Page 1 of 5 LEGAL_1: Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018 Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at

More information

For personal use only

For personal use only ASX ANNOUNCEMENT AGM PRESENTATION SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders. End Contact: Maria Halasz,

More information

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

CV SCIENCES, INC. (Exact name of registrant as specified in its charter)

CV SCIENCES, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Career Education Corporation Bear Stearns 2007 SMid-Cap Investor Conference

Career Education Corporation Bear Stearns 2007 SMid-Cap Investor Conference Career Education Corporation Bear Stearns 2007 SMid-Cap Investor Conference November 13, 2007 Safe Harbor This presentation contains certain forward-looking statements, as defined in Section 21E of the

More information

EQUITY RAISING OF $9.6M CONCLUDED HIGHLIGHTS

EQUITY RAISING OF $9.6M CONCLUDED HIGHLIGHTS EQUITY RAISING OF $9.6M CONCLUDED ASX Announcement 7 November 2018 ASX: Code P03 Issued Shares 31,382,956 Directors/Management Steve Morris Chairman Steve Annear Executive Director Simon Lill Executive

More information

FS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP. Combining FSIC & CCT platforms to create stockholder value

FS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP. Combining FSIC & CCT platforms to create stockholder value FS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP Combining FSIC & CCT platforms to create stockholder value FS INVESTMENTS AND KKR TO ESTABLISH INDUSTRY-LEADING PARTNERSHIP FS Investments ( FS ) and KKR

More information

CeQur establishes Wales subsidiary

CeQur establishes Wales subsidiary FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,

More information

INVESTOR PRESENTATION!

INVESTOR PRESENTATION! INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING

More information

Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance

Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance Corporate Communications Department NEWS Release Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance $468 million returned to shareholders through share repurchases Completed

More information

Investor Presentation. August 2017 OTCQB: ZYXI

Investor Presentation. August 2017 OTCQB: ZYXI Investor Presentation August 2017 Forward Looking Statements Statements made in this presentation include financial estimates and forwardlooking statements that are not historical facts. Each of these

More information

INTERNATIONAL WINTER SCHOOL

INTERNATIONAL WINTER SCHOOL INTERNATIONAL WINTER SCHOOL RESEARCH PROMOTION, TECHNOLOGY TRANSFER AND BUSINESS CREATION November 22nd 2010, Alexandria, Egypt Anita COHEN Délégation à la Recherche Clinique et à l'innovation 80 rue Brochier

More information

Purvi B. Maniar Member of the Firm

Purvi B. Maniar Member of the Firm Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the

More information

Shell s Journey to Mobility

Shell s Journey to Mobility Shell s Journey to Mobility Speakers: Yorinde Knegtering Business Analyst, IT Produce Hydrocarbons Prabhat Mishra Product Owner, PI Center of Excellence Definitions & cautionary note Reserves: Our use

More information

Shell Project Delivery Best Practices Dick L. Wynberg, GM NOV Projects Integrated Gas Shell Global Solutions International B.V

Shell Project Delivery Best Practices Dick L. Wynberg, GM NOV Projects Integrated Gas Shell Global Solutions International B.V Shell Project Delivery Best Practices Dick L. Wynberg, GM NOV Projects Integrated Gas Shell Global Solutions International B.V SEPTEMBER 26, 2017, ST. PETERSBURG, HOTEL ASTORIA Definitions and cautionary

More information

BRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12

BRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12 BRUKER CORP FORM 8-K (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12 Address 40 MANNING RD BILLERICA, MA, 01821 Telephone 978663-3660 CIK 0001109354 Symbol BRKR SIC Code 3826 - Laboratory

More information

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017 KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform December 2017 Strategic BDC Partnership Introduction On December 11, 2017, KKR and FS Investments

More information

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital August 14, 2017 ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital To Acquire One of Ten License Holders in New

More information

Network-1 Technologies, Inc.

Network-1 Technologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

BOVIE MEDICAL CORPORATION

BOVIE MEDICAL CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

2,500,000 Shares. Common Stock

2,500,000 Shares. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15

More information

Operational Intelligence to deliver Smart Solutions

Operational Intelligence to deliver Smart Solutions Operational Intelligence to deliver Smart Solutions Presented by John de Koning Shell Global Solutions DEFINITIONS AND CAUTIONARY NOTE Reserves: Our use of the term reserves in this presentation means

More information

Nasdaq: RNVA. Diagnostics and supportive software solutions to healthcare providers.

Nasdaq: RNVA. Diagnostics and supportive software solutions to healthcare providers. Nasdaq: RNVA Diagnostics and supportive software solutions to healthcare providers. Forward looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova

More information

Action: Notice of an application for an order under sections 6(c), 12(d)(1)(J), and 57(c) of the

Action: Notice of an application for an order under sections 6(c), 12(d)(1)(J), and 57(c) of the This document is scheduled to be published in the Federal Register on 05/23/2014 and available online at http://federalregister.gov/a/2014-11965, and on FDsys.gov 8011-01p SECURITIES AND EXCHANGE COMMISSION

More information

MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS REGULATED INFORMATION MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS Liège, Belgium 1 September 2016, 07h30 Mithra Pharmaceuticals, a leader in Women s

More information

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn

More information

Fortis to acquire strategic stake in Parkway Holdings, Singapore

Fortis to acquire strategic stake in Parkway Holdings, Singapore PRESS RELEASE Fortis to acquire strategic stake in Parkway Holdings, Singapore Landmark cross border deal in Healthcare sector out of India Move will establish Fortis as Asia s largest hospital network

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

In the quarter, Textron returned $344 million to shareholders through share repurchases, compared to $186 million in the first quarter of 2017.

In the quarter, Textron returned $344 million to shareholders through share repurchases, compared to $186 million in the first quarter of 2017. Corporate Communications Department NEWS Release Textron Reports First Quarter 2018 Income from Continuing Operations of $0.72 per Share; Signs Agreement to Sell Tools & Test Business for $810 Million

More information

2 nd Quarter Earnings Conference Call

2 nd Quarter Earnings Conference Call 2 nd Quarter Earnings Conference Call KKR & Co. Inc. Investor Update July 26, 2018 Recent Milestones K-1 $ Converted to a Corporation on July 1, 2018 Investor Day held on July 9, 2018 2 Key Metrics Assets

More information

Robert A. Greising Partner

Robert A. Greising Partner Robert A. Greising Partner P: (317) 238-6215 F: (317) 636-1507 E: rgreising@kdlegal.com Indianapolis Office One Indiana Square Suite 2800 Indianapolis, IN 46204-2079 Robert Greising is a Partner in the

More information

Robert A. Greising Partner

Robert A. Greising Partner Robert A. Greising Partner P: (317) 238-6215 F: (317) 636-1507 E: rgreising@kdlegal.com Indianapolis Office One Indiana Square Suite 2800 Indianapolis, IN 46204-2079 Robert Greising serves as a Partner

More information

Operational Intelligence to Deliver Smart Solutions. Copyright 2015 OSIsoft, LLC

Operational Intelligence to Deliver Smart Solutions. Copyright 2015 OSIsoft, LLC Operational Intelligence to Deliver Smart Solutions Presented by John de Koning DEFINITIONS AND CAUTIONARY NOTE Reserves: Our use of the term reserves in this presentation means SEC proved oil and gas

More information

ACACIA RESEARCH GROUP LLC

ACACIA RESEARCH GROUP LLC ACACIA RESEARCH GROUP LLC ACACIA UNLOCKING RESEARCH patent GROUP, POTENTIAL LLC NASDAQ: ACTG A Subsidiary of Acacia Research Corporation Forward Looking Statements This presentation contains forward looking

More information

Fourth Quarter 2013 Results. February 6, 2014

Fourth Quarter 2013 Results. February 6, 2014 Fourth Quarter 2013 Results February 6, 2014 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. Inc. Investor Update February 1, 2019 Key Metrics Assets Under Management Management Fees ($ in billions) ($ in millions) $195 $1,069 $168 $905 $100 $107

More information

BLUEKNIGHT ENERGY PARTNERS, L.P.

BLUEKNIGHT ENERGY PARTNERS, L.P. BLUEKNIGHT ENERGY PARTNERS, L.P. FORM 8-K (Current report filing) Filed 09/19/12 for the Period Ending 09/13/12 Address 201 NW 10TH, SUITE 200 OKLAHOMA CITY, OK, 73103 Telephone (405) 278-6400 CIK 0001392091

More information

Second Quarter 2013 Results August 1, 2013

Second Quarter 2013 Results August 1, 2013 Second Quarter 203 Results August, 203 2 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)

More information

Investor Presentation. November 2018

Investor Presentation. November 2018 Investor Presentation November 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn of Assets $81bn Private Equity, Growth Equity

More information

Sony IR Day Game & Network Services Segment. November 25, Andrew House

Sony IR Day Game & Network Services Segment. November 25, Andrew House Sony IR Day 2014 November 25, 2014 Andrew House President and Group CEO Sony Computer Entertainment Inc. Group Executive in Charge of Network Entertainment Business Sony Corporation Agenda 1. Business

More information

Daseke Adds Three Companies; Annual Revenue Run Rate Grows to $1.2 Billion

Daseke Adds Three Companies; Annual Revenue Run Rate Grows to $1.2 Billion NEWS RELEASE Daseke Adds Three Companies; Annual Revenue Run Rate Grows to $1.2 Billion 12/4/2017 Growing from $30 million in nine years ADDISON, Texas--(BUSINESS WIRE)-- Daseke,Inc. (NASDAQ: DSKE) (NASDAQ:

More information

Goldman Sachs Medtech Conference, 9 September Dave Illingworth CEO

Goldman Sachs Medtech Conference, 9 September Dave Illingworth CEO Goldman Sachs Medtech Conference, 9 September Dave Illingworth CEO 0 Forward looking statements This presentation contains certain "forward-looking statements" within the meaning of the US Private Securities

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

Rationale for the proposed transaction

Rationale for the proposed transaction PRESS RELEASE Fortis Healthcare Limited Board of Directors approves demerger of its diagnostics business into a separate listed Company through a composite scheme of arrangement Gurgaon, August 19, 2016

More information

Network-1 Technologies, Inc.

Network-1 Technologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K. TEXTRON INC. (Exact name of Registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K. TEXTRON INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Kandace P. Watson Partner

Kandace P. Watson Partner Kandace P. Watson Partner 12275 El Camino Real Suite 200 San Diego, CA 92130 T: 858.720.8930 F: 858.523.6770 kwatson@sheppardmullin.com Practices Healthcare Corporate Mergers and Acquisitions Technology

More information

THE STARS GROUP 2017 ANNUAL AND SPECIAL MEETING MANAGEMENT PRESENTATION MAY 10, 2018, TORONTO, 11:30 (ET)

THE STARS GROUP 2017 ANNUAL AND SPECIAL MEETING MANAGEMENT PRESENTATION MAY 10, 2018, TORONTO, 11:30 (ET) Please Note: THE STARS GROUP 2017 ANNUAL AND SPECIAL MEETING MANAGEMENT PRESENTATION MAY 10, 2018, TORONTO, 11:30 (ET) Some of our comments today will contain forward-looking information and statements

More information

Chapter 5. Forms of Business Ownership and Organization

Chapter 5. Forms of Business Ownership and Organization Chapter 5 Forms of Business Ownership and Organization Learning Objectives 1 2 Discuss why most businesses are small businesses. Determine the contributions of small businesses to the economy. 7 Outline

More information

NASDAQ: CASI Partnering Presentation

NASDAQ: CASI Partnering Presentation NASDAQ: CASI Partnering Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to

More information

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D. Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology

More information

peace of mind For from development to commercial supply

peace of mind For from development to commercial supply For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number

More information

Accenture plc (Exact name of registrant as specified in its charter)

Accenture plc (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook

Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

First Quarter 2014 Results

First Quarter 2014 Results First Quarter 04 Results May 6, 04 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor

More information

HEALTHCARE ADVISORY SERVICES

HEALTHCARE ADVISORY SERVICES HEALTHCARE ADVISORY SERVICES Building Value In Healthcare Real Estate HEALTHCARE ADVISORY SERVICES TRANSWESTERN REAL ESTATE SERVICES DEDICATED TO HEALTHCARE Transwestern s Healthcare Advisory Services

More information

Cannabis Practice Group

Cannabis Practice Group Cannabis Practice Group McMillan LLP Vancouver Calgary Toronto Ottawa Montréal Hong Kong Cannabis mcmillan.ca Practice Group 1 Medical cannabis is booming and McMillan is at the forefront of developments

More information

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People February 1, 2018 ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People Company to Host a Conference Call at 9:00am ET on

More information

Innovation and the Changing Practice of Medicine

Innovation and the Changing Practice of Medicine Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis

More information

PreveCeutical Closes Private Placement and Completes Amalgamation and Reverse Take-Over Transaction and Announces Resumption of Trading

PreveCeutical Closes Private Placement and Completes Amalgamation and Reverse Take-Over Transaction and Announces Resumption of Trading PreveCeutical Closes Private Placement and Completes Amalgamation and Reverse Take-Over Transaction and Announces Resumption of Trading July 10 th, 2017, Vancouver, British Columbia: PreveCeutical Medical

More information